Top news of the week: 14.07.2020.

#lifesciences #biospace #biotechnology #pharmaceuticals #coronavirus #COVID #vaccine #COVID19 #pandemic #RegulatoryAffairs

Career And Jobs

On Jul 8, 2020
@Biotechnology shared
3 Ways the Biotech Industry Offers Work-Life Balance https://t.co/4X5gHtVNlp https://t.co/GDX1E3ZeDE
Open

3 Ways the Biotech Industry Offers Work-Life Balance

3 Ways the Biotech Industry Offers Work-Life Balance

What factors do you think affect burnout? Do you think some industries are more prone to burnout than others?

On Jul 9, 2020
@JohnCendpts shared
#3 After psilocybin and ketamine, a new biotech comes along developing a drug @ScottGottliebMD fought by @Jasonmmast https://t.co/aDaNGVGg9r
Open

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day in August 2016, he learned he might have only 30 days before the government made him destroy his ...

On Jul 9, 2020
@BiotechWorld shared
Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera https://t.co/G8Kc3YxVzm https://t.co/Fxuj3yOuA0
Open

Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera

Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera Therapeutics.

On Jul 9, 2020
@JohnCendpts shared
RT @JMaraganore: The bottom line here is we need access to the best people around the world to do what we do as a business to fight disease... anti-immigration policies just tip the balance in favor of disease over science and medicine. https://t.co/g6tLQoQOY1
Open

Mass. businesses say Trump’s ban on foreign-worker visas is making it difficult to fill jobs

Mass. businesses say Trump’s ban on foreign-worker visas is making it difficult to fill jobs

Employers say many of the jobs affected by the freeze — ranging from seasonal labor to highly skilled tech jobs — can’t necessarily be filled by Americans.

On Jul 10, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: July 10 #biospace #lifesciences #biotechnology #pharmaceuticals #COVID-19 #coronavirus #pandemic #COVID19 #vaccine https://t.co/Rf9kJHb5ay
Open

Biopharma Update on the Novel Coronavirus: July 10

Biopharma Update on the Novel Coronavirus: July 10

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.

On Jul 13, 2020
@Proclinical shared
Time for a new role? Check out our latest regulatory affairs jobs. https://t.co/mBRWTJm39I #GlobalGrowthPartners #Staffing #RegulatoryAffairs https://t.co/CyFEZbQVLy
Open

Regulatory Affairs jobs

Regulatory Affairs jobs

Apply online for Regulatory Affairs jobs. Recruitment for permanent & contract reg affairs associate & manager vacancies in pharma, biotech, medical devices, cosmetics and nutrition.

On Jul 10, 2020
@BioWorld shared
China's Sinovac phase III trials in Brazil could take as little as three months https://t.co/olOlmZQ5Rn
Open

China's Sinovac phase III trials in Brazil could take as little as three months

China's Sinovac phase III trials in Brazil could take as little as three months

CAJICA, Colombia, and BEIJING – Last week Sinovac Biotech Ltd., of Beijing, announced the approval by Anvisa, the Brazilian health care surveillance agency, to start phase III trials to ...

On Jul 8, 2020
@biospace shared
Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients #biospace #lifesciences #biotechnology #pharmaceuticals #cancer https://t.co/xzIqKueguw
Open

Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients

Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients

Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary ...